OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
about
Current status and future directions of botulinum neurotoxins for targeting pain processingDevelopment of onabotulinumtoxinA for chronic migraineProspective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.Primary headache disorders and neuro-ophthalmologic manifestations.Therapeutic use of botulinum toxin in migraine: mechanisms of action.Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigmDiagnosis and treatment for chronic migraineTreatment of Morton neuroma with botulinum toxin A: a pilot study.OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.Impact of botulinum toxin a on the quality of life of subjects following treatment of facial lines.Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal.Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.The Use of Complementary and Alternative Medicine in Patients with MigraineBotulinum toxin in the management of chronic migraine: clinical evidence and experience.Antidromic vasodilatation and the migraine mechanism.OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.Emerging treatment for chronic migraine and refractory chronic migraine.Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review.Beyond Beauty: Onobotulinumtoxin A (BOTOX®) and the Management of Migraine HeadachesGlutamate receptor antagonists in the management of migraine.Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management.P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice.The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.Global Updates on the Future Directions of Neurotoxins and Fillers.Anatomical Regional Targeted (ART) BOTOX Injection Technique: A Novel Paradigm for Migraines and Chronic Headaches.Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations.A 3-month analysis of disability, quality of life, and disease course in patients with migraine.Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse.Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.The impact of cognitive symptoms on migraine attack-related disability.
P2860
Q26778129-EBBA5484-8A2C-463E-9A4F-6ECE10136A8CQ27027006-BD1C9602-62B1-42B2-AF0E-6F562790F608Q30846961-F956BF77-1C2F-401D-8A20-CA5634A96BADQ33702135-1D55115F-89B2-4062-A19F-B726876A038BQ34419654-C10CDFF1-45AA-419A-87BC-1E4A64D8B31EQ34806387-A154FB71-7CD8-44DC-97D0-E973B204A116Q35121186-6EE40094-6F97-48A7-8A6C-63C89D9C6BE2Q35435213-67092AF6-3F5A-488D-89FA-1D537C0902E1Q36925875-419CC2AB-A079-4C95-BFD9-0A531D84CD13Q36952082-411EAABA-A754-4805-B04E-4A1D0B8485FFQ37121894-79747501-5F05-4313-BCCF-1AFB8D117D0DQ37191700-047CEE8A-1C5B-43C7-AF37-122226E0983FQ37314099-228B603C-FB4B-4A6C-9214-A39AADFDE583Q37430202-C24C90EF-2CCA-447B-8BF5-70475ED74C16Q37650532-4FC5DC5A-537F-44CA-B6F9-46EBCC8DA359Q37703849-D1A9595D-B93A-49E6-9BBA-150A4B0AC210Q37722781-7619CAC9-6DC9-4C09-B51C-CCE6C70A1EFEQ37971447-C6D5198E-E983-4BFC-9411-3571A329B883Q37999053-E5145EB5-000E-45DE-8FA3-ECAF8625AC8BQ38031982-656B93E8-4642-4557-9E97-B2E1BFC4AEF4Q38066464-EB921EF2-E0E7-43F5-9A0A-7BCEFDED056CQ38162211-41A7F0FF-6EE0-4FBB-9661-FC2336907BD5Q38230246-AE9EBE12-BCD4-4102-89ED-3A35422FDBEDQ38255772-49446CF6-9643-421E-B902-08495A1EB648Q38553021-C0E41F67-58F4-4507-87E3-0D7F2F126EE9Q38647473-AFC4463A-57A2-48A2-8257-D1C2FC1DBEE6Q38778077-C27953B9-96A1-4BFB-9029-DE3D9E7604D1Q39158436-F0026205-B143-4AC7-A51F-E588C1C134D2Q40183047-D1625646-AED8-491B-A5D2-647635263A9AQ40527490-AA0EBA43-B78C-4D53-99A9-18488770F982Q42370565-97DE207C-6626-4129-933B-5057ADC8E081Q43688441-06CC7053-9FFA-457C-85A6-577543825E30Q45376934-A231C77D-BE7B-4E0D-A7E5-40185DCA5A91Q46698001-04C1E919-5337-4C9B-8C9D-46F1CC9BC7A6Q47410678-D71928C4-10F1-468C-AD91-838E51D39DBFQ47420416-D5CC94C2-682F-4495-8925-16175A88AFD9Q47785285-22A95B6A-B511-423B-BC68-8661B0F455F7Q48418075-40BCBB4C-8295-4010-AD44-AEAEB9FC5156Q48505652-D7343E2B-C470-4641-B205-AE1424657C0CQ50568715-BE72CF78-88E6-42D0-B62F-0D1ED5D3523B
P2860
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@en
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@nl
type
label
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@en
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@nl
prefLabel
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@en
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@nl
P2093
P1433
P1476
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
@en
P2093
B Grosberg
C C Turkel
D W Dodick
P J McAllister
R E DeGryse
S D Silberstein
S K Aurora
P304
P356
10.1212/WNL.0B013E318232AB65
P407
P577
2011-09-28T00:00:00Z